Concepedia

A. U. Pande

AU

12

Publications

328

Citations

11

H-Index

2006

Active since

Affiliations

Roswell Park Comprehensive Cancer Center(Current)

A. U. Pande is an author at Roswell Park Comprehensive Cancer Center specializing in pharmacotherapy, medicine, and radiation oncology.

Top concepts

Publications per year

2006–2021

12

Publications

12

Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.

A. U. Pande, Jeffrey Lombardo, Edward Spangenthal et al. · PubMed · 2007 · 89 citations

, , +14

Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT).

Lorenza Rimassa, Camillo Porta, Ivan Borbath et al. · Journal of Clinical Oncology · 2012 · 36 citations

, , +21

Pilot Study of Gefitinib, Oxaliplatin, and Radiotherapy for Esophageal Adenocarcinoma

Milind Javle, A. U. Pande, Renuka Iyer et al. · American Journal of Clinical Oncology · 2008 · 34 citations

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study

Milind Javle, Jihnhee Yu, Christopher R. Garrett et al. · British Journal of Cancer · 2009 · 33 citations · Full text

Concurrent Oxaliplatin, 5-Fluorouracil, and Radiotherapy in the Treatment of Locally Advanced Esophageal Carcinoma

Brigid M. O'Connor, Manpreet Chadha, A. U. Pande et al. · The Cancer Journal · 2007 · 23 citations

Rows per page

1–5 of 12